CoChat

Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial

Open access
The Look AHEAD Research Group · 2014 · Diabetes Care

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: We examined the effects of an intensive lifestyle intervention (ILI), compared with a diabetes support and education (DSE) control intervention, on long-term changes in depression symptoms, antidepressant medication (ADM) use, and health-related quality of life (HRQoL) in overweight/obese individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: Look AHEAD was a multisite randomized controlled trial of 5,145 overweight/obese participants assigned to ILI (designed to produce weight loss) or DSE and followed for a median of 9.6 years. The Beck Depression Inventory (BDI) was administered at baseline, annually at years 1–4, and again at year 8. Mean BDI scores and incidence of BDI scores ≥10, indicative of likely mild or greater depression, were examined. Annually through year 10, participants reported their ADM use and completed the Medical Outcomes Study Short Form 36 (SF-36) questionnaire, which yields physical component summary (PCS) and mental component summary (MCS) scores. RESULTS: ILI significantly reduced the incidence of mild or greater depression symptoms (BDI scores ≥10) compared with DSE (hazard ratio [HR] = 0.85; 95% CI 0.75–0.97; P = 0.0145). Although SF-36 PCS scores worsened over time in both groups, ILI participants reported better physical function than DSE throughout the first 8 years (all P values <0.01). There were no significant differences between treatment arms in the proportion of participants who used ADMs or in SF-36 MCS scores. CONCLUSIONS: ILI for overweight/obese patients with type 2 diabetes may reduce the risk of developing clinically significant symptoms of depression and preserve physical HRQoL. These findings should be considered when evaluating the potential benefits of ILIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc13-1928

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CONSORT flow diagram.
Figure 1 CONSORT flow diagram.CC BY-NC-ND · PubMed Central
Figure 2 (A) Cumulative HR (ILI versus DSE) for incidence of BDI ≥10 over 8 years in participants with BDI <10 at baseline. (B) Mean BDI score over 8 years by treatment arm for the full sample of participants. The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. (C) Mean BDI score over 8 years by treatment arm for participants with a baseline BDI score <10 (indicative of no/minimal symptoms of depression). The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. (D) Mean BDI score over 8 years by treatment arm for participants with a baseline BDI score ≥10 (indicative of mild or greater symptoms of depression). The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. *, significant differences between groups (P < 0.005).
Figure 2 (A) Cumulative HR (ILI versus DSE) for incidence of BDI ≥10 over 8 years in participants with BDI <10 at baseline. (B) Mean BDI score over 8 years by treatment arm for the full sample of participants. The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. (C) Mean BDI score over 8 years by treatment arm for participants with a baseline BDI score <10 (indicative of no/minimal symptoms of depression). The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. (D) Mean BDI score over 8 years by treatment arm for participants with a baseline BDI score ≥10 (indicative of mild or greater symptoms of depression). The sample size for DSE appears above the sample size for ILI for each year the BDI was administered. *, significant differences between groups (P < 0.005).CC BY-NC-ND · PubMed Central
Figure 3 (A) Mean PCS scores over 10 years by treatment arm. The sample size for DSE appears the above sample size for ILI. *, significant differences between groups (P < 0.005). (B) Mean MCS scores over 10 years by treatment arm. The sample size for DSE appears above the sample size for ILI.
Figure 3 (A) Mean PCS scores over 10 years by treatment arm. The sample size for DSE appears the above sample size for ILI. *, significant differences between groups (P < 0.005). (B) Mean MCS scores over 10 years by treatment arm. The sample size for DSE appears above the sample size for ILI.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. Beck, 1987, Manual for the Beck Depression Inventory
  2. Beck, 1996, Manual for the Beck Depression Inventory-II
  3. World Health Organization, 2008, The Global Burden of Disease: 2004 Update

Cited by

Metadata

Authors
The Look AHEAD Research Group
Affiliations
Association on Higher Education And Disability (US)
Corresponding author
The Look AHEAD Research Group
Venue
Diabetes Care
Published
2014-05-10
Volume
37
Issue
6
Pages
1544-1553
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W984807221
Cited by
217
References
40
Citations by year
2026: 10 · 2025: 9 · 2024: 14 · 2023: 19 · 2022: 22 · 2021: 9 · 2020: 19 · 2019: 16 · 2018: 17 · 2017: 33 · 2016: 21 · 2015: 15 · 2014: 12
FWCI
21.61
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Health and Human Services
  • U.S. Department of Veterans Affairs (M01RR01346)
  • Eli Lilly and Company
  • AstraZeneca
  • Sanofi
  • New York City Department of Health and Mental Hygiene
  • Massachusetts General Hospital (DK57151, UL1-RR024153, DK57219, DK57182, M01RR01066, DK57008, DK57178, DK57154, M01RR00051, DK57136, P30 DK48520, DK57171, DK57177, DK57149, DK57002, M01RR000056, DK56992, DK 046204, M01RR02719, M01RR01346, DK56990, DK57131, M01RR0021140, DK57078, DK57135)
  • Kaiser Permanente
  • Massachusetts Institute of Technology (DK 046204, P30 DK48520, DK57182, DK57154, DK57002, DK57149, DK57178, M01RR01346, DK57135, DK57171, DK57151, DK57078, M01RR02719, UL1 RR 024153, DK57008, M01RR01066, M01RR000056, DK56990, DK57177, DK56992, M01RR0021140, DK57219, DK57136, DK57131, M01RR00051)
  • University of Pennsylvania
  • Alere
  • Johns Hopkins University (M01RR02719)
  • University of Pittsburgh (DK57131, DK57008, DK57154, M01RR01346, M01RR01066, DK57078, DK56990, DK57178, DK57002, DK57177, DK56992, P30 DK48520, DK 046204, M01RR02719, UL1RR024153, DK57151, M01RR0021140, DK57149, M01RR000056, M01RR00051, DK57136, DK57171, DK57219, DK57182, DK57135)
  • Herbalife Nutrition
  • Novo Nordisk
  • National Institutes of Health (M01RR0021140, UL1TR001120, UL1TR001082, 046204, 5p30dk046204-15, DK48520, DK 046204, DK57002)
  • Centers for Disease Control and Prevention (M01RR02719, M01RR000056, DK57135, DK57154, UL1RR024153, DK57131, M01RR00051, DK 046204, DK57008, M01RR01346, DK56992, M01RR0021140, DK57177, DK57151, P30 DK48520, M01RR01066, DK57182, DK57171, DK56990, DK57136, DK57149, DK57078, DK57219, DK57002, DK57178)
  • National Heart, Lung, and Blood Institute (DK57219, DK57131, DK57154, DK57151, K23HL109235, DK56992, DK57078, DK57177, M01RR0021140, DK 046204, DK57182, DK57002, DK57149, DK57008, DK57135, DK57136, DK57178, DK56990, DK57171)
  • National Institute of Nursing Research (DK57219, DK57008, M01RR0021140, DK57002, DK57177, DK57171, DK57182, DK57135, DK57131, DK 046204, DK57151, DK57136, DK56990, DK57178, DK57078, DK56992, DK57149)
  • National Institute of Diabetes and Digestive and Kidney Diseases (M01RR0021140, DK48520, DK-57171, DK 57136, DK57149, P30DK050456, DK 57002, DK57182, DK56990, (DK 046204, DK57008, DK57177, DK 57078, DK57219, U01DK057149, DK-57178, U01DK057151, U01DK057135, U01DK057131, U01DK056990, R01DK081472, DK-57135, U01DK057136, DK-56992, DK57154, U01DK057178, U01DK057182, U01DK057078, U01DK057154, P30DK079637, U01DK057008, U01DK057171, DK57131, U01DK057002, U01DK057219, U01DK056992, U01DK057177, P30DK017047, P30DK048520, DK 57151, P30-DK046204)
  • National Center on Minority Health and Health Disparities (DK57136, DK57171, DK57182, DK57154, DK57177, DK 046204, DK57135, M01RR0021140, DK57008, DK57178, DK57002, DK57151, DK56990, DK57078, DK56992, DK57149, DK57219, DK57131)
  • National Center for Research Resources (M01RR002719, M01RR000056, M01RR000051, M01RR001066, M01RR001346, UL1RR024153)
  • Office of Research on Women's Health (M01RR02719, DK57008, DK57135, DK56990, DK57002, P30 DK48520, DK57177, DK56992, DK57182, DK57151, DK57149, DK57219, DK57078, M01RR000056, M01RR01346, DK57171, UL1 RR 024153, DK57178, M01RR01066, M01RR00051, DK57154, DK57136, DK57131, DK 046204, M01RR0021140)
  • National Center for Advancing Translational Sciences
  • National Institute on Minority Health and Health Disparities (P20MD006899)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
intensive lifestyle intervention, type 2 diabetes, depression, health-related quality of life, antidepressant use, overweight and obesity, weight loss, diabetes support and education, Look AHEAD trial, physical function
MeSH terms
Antidepressive Agents, Depression, Diabetes Mellitus, Type 2, Female, Humans, Life Style, Male, Middle Aged, Obesity, Quality of Life, Surveys and Questionnaires, Weight Loss, Treatment Outcome, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.